Brenda I. Anosike 1
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Brenda I. Anosike 1 has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Salih Demirhan
Department of Pediatrics, Division of Infectious Diseases University of Health Sciences, Kayseri City Hospital Kayseri Türkiye
2 shared publications - Betsy C. Herold
Division of Pediatric Infectious Diseases at the Children’s Hospital at Montefiore and the Albert Einstein College Medicine
1 shared publication - Elia D. Rackovsky
Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons Division of Pediatric Critical Care, Harlem Hospital Center New York New York USA
1 shared publication - Ilir Agalliu
Department of Epidemiology and Population Health, Albert Einstein College of Medicine , Bronx, NY
1 shared publication Kevin Burgos
Department of Pediatrics, Albert Einstein College of Medicine
1 shared publicationKiriam Escobar Lee
Department of Pediatrics, Albert Einstein College of Medicine
1 shared publication
Latest Publications
- 23 September 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (9) , e71847
Residence‐Associated Differences in Airway Microbiology Among Tracheostomy‐Dependent Children
Background: Tracheostomy‐dependent children (TDC) experience chronic airway instrumentation and frequent healthcare exposure, increasing their risk for colonization and infection with multidrug‐resistant organisms (MDROs). Most TDC reside either in the community or in healthcare facilities, yet the impact of residential setting on airway microbiology in these children is not well characterized. Methods: We conducted a retrospective chart review of TDC ≤ 18 years admitted to an academic tertiary pediatric intensive care unit (PICU) between Jan 2017 and Dec 2022 who underwent tracheal aspirate cultures (TACs) within 72 h of admission. Airway microbiology and MDRO prevalence were compared between children presenting from healthcare facilities and the community. Multivariate mixed‐effect logistic regression models evaluated factors associated with MDRO isolation, adjusting for age, number of admissions, and cuffed tracheostomy status. Results: Among 109 children (282 admissions; 207 community, 75 facility), facility residence was associated with higher odds of isolating any MDROs in bivariate analysis (OR 2.73 95% CI 1.19–6.25 p = 0.017). In multivariate analysis, ≥ 5 prior hospital admissions and cuffed tracheostomy remained independently associated with MDRO isolation. Although facility residence no longer retained statistical significance after adjustment, the adjusted odds ratio remained similar to the bivariate estimate. Conclusions: Healthcare facility residence is associated with increased MDRO isolation. Cumulative healthcare exposure and cuffed tracheostomy status may also be important risk factors for MDRO presence. Respiratory microbiology differs between facility‐ and community‐based TDC. Awareness of local airway microbiologic patterns and cumulative healthcare exposure may improve interpretation of TACs and guide empiric antimicrobial therapy.
- 23 September 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (9) , e71847
Residence‐Associated Differences in Airway Microbiology Among Tracheostomy‐Dependent Children
Background: Tracheostomy‐dependent children (TDC) experience chronic airway instrumentation and frequent healthcare exposure, increasing their risk for colonization and infection with multidrug‐resistant organisms (MDROs). Most TDC reside either in the community or in healthcare facilities, yet the impact of residential setting on airway microbiology in these children is not well characterized. Methods: We conducted a retrospective chart review of TDC ≤ 18 years admitted to an academic tertiary pediatric intensive care unit (PICU) between Jan 2017 and Dec 2022 who underwent tracheal aspirate cultures (TACs) within 72 h of admission. Airway microbiology and MDRO prevalence were compared between children presenting from healthcare facilities and the community. Multivariate mixed‐effect logistic regression models evaluated factors associated with MDRO isolation, adjusting for age, number of admissions, and cuffed tracheostomy status. Results: Among 109 children (282 admissions; 207 community, 75 facility), facility residence was associated with higher odds of isolating any MDROs in bivariate analysis (OR 2.73 95% CI 1.19–6.25 p = 0.017). In multivariate analysis, ≥ 5 prior hospital admissions and cuffed tracheostomy remained independently associated with MDRO isolation. Although facility residence no longer retained statistical significance after adjustment, the adjusted odds ratio remained similar to the bivariate estimate. Conclusions: Healthcare facility residence is associated with increased MDRO isolation. Cumulative healthcare exposure and cuffed tracheostomy status may also be important risk factors for MDRO presence. Respiratory microbiology differs between facility‐ and community‐based TDC. Awareness of local airway microbiologic patterns and cumulative healthcare exposure may improve interpretation of TACs and guide empiric antimicrobial therapy.
- 9 January 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (4) , e140-e141
A Rare Presentation of Late Latent Syphilis With Alopecia and Polyarticular Joint Pain in a 17-Year-old Teenager
- 9 January 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (4) , e140-e141
A Rare Presentation of Late Latent Syphilis With Alopecia and Polyarticular Joint Pain in a 17-Year-old Teenager
- 4 September 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (1) , 33-39
Pediatric Clinical Outcomes of Nasal Methicillin-resistant Staphylococcus aureus Polymerase Chain Reaction Utilization
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a clinical challenge in selecting empiric antimicrobials for pediatric infections. We implemented nasal MRSA polymerase chain reaction (nMRSA PCR) screening as a diagnostic tool and evaluated its impact on empiric antibiotic use and clinical outcomes. Methods: A retrospective single-center study of patients hospitalized with infections who were empirically prescribed anti-MRSA antibiotics was conducted prior to and following the initiation of nMRSA PCR screening. Electronic medical records, pharmacy data and bacterial cultures results were reviewed. Predictive values of nMRSA PCR testing were calculated and the duration of anti-MRSA empiric therapy and clinical outcomes preimplementation and postimplementation were compared. Results: During the preimplementation period, there were 382 distinct episodes (294 unique patients) that met the inclusion criteria and during post-nMRSA PCR implementation, 394 episodes (360 unique patients) were identified. The median time to discontinuation of anti-MRSA antibiotics and proportion of patients prescribed anti-MRSA antibiotics at discharge were significantly lower in postimplementation compared with preimplementation period; 48 versus 56 hours, P < 0.001 and 20.1% versus 40.3%, P < 0.001, respectively. The negative and positive predictive values of nMRSA PCR compared to clinical culture results were 95.6% and 51.2%, respectively. Predefined adverse outcomes were documented in 11 patients who had early anti-MRSA discontinuation with negative nMRSA PCR results but only 3 were restarted on anti-MRSA treatment and none grew MRSA in clinical cultures. Conclusions: Shortened anti-MRSA antibiotic duration, high negative predictive value and low adverse events provide promising evidence that nMRSA PCR is an effective, rapid antimicrobial stewardship tool for hospitalized children.
- 4 September 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (1) , 33-39
Pediatric Clinical Outcomes of Nasal Methicillin-resistant Staphylococcus aureus Polymerase Chain Reaction Utilization
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a clinical challenge in selecting empiric antimicrobials for pediatric infections. We implemented nasal MRSA polymerase chain reaction (nMRSA PCR) screening as a diagnostic tool and evaluated its impact on empiric antibiotic use and clinical outcomes. Methods: A retrospective single-center study of patients hospitalized with infections who were empirically prescribed anti-MRSA antibiotics was conducted prior to and following the initiation of nMRSA PCR screening. Electronic medical records, pharmacy data and bacterial cultures results were reviewed. Predictive values of nMRSA PCR testing were calculated and the duration of anti-MRSA empiric therapy and clinical outcomes preimplementation and postimplementation were compared. Results: During the preimplementation period, there were 382 distinct episodes (294 unique patients) that met the inclusion criteria and during post-nMRSA PCR implementation, 394 episodes (360 unique patients) were identified. The median time to discontinuation of anti-MRSA antibiotics and proportion of patients prescribed anti-MRSA antibiotics at discharge were significantly lower in postimplementation compared with preimplementation period; 48 versus 56 hours, P < 0.001 and 20.1% versus 40.3%, P < 0.001, respectively. The negative and positive predictive values of nMRSA PCR compared to clinical culture results were 95.6% and 51.2%, respectively. Predefined adverse outcomes were documented in 11 patients who had early anti-MRSA discontinuation with negative nMRSA PCR results but only 3 were restarted on anti-MRSA treatment and none grew MRSA in clinical cultures. Conclusions: Shortened anti-MRSA antibiotic duration, high negative predictive value and low adverse events provide promising evidence that nMRSA PCR is an effective, rapid antimicrobial stewardship tool for hospitalized children.
- Open Access
- 2 September 2024
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 59 (5) , 469-475
Clinical Outcomes of Oral Antibiotic Switch in Children with Staphylococcus aureus Bacteremia
Objective: Staphylococcus aureus is one of the leading causes of bacteremia in children. In this study, we aimed to evaluate our center’s experience on the etiology, management, and outcomes of pediatric Staphylococcus aureus bacteremia (SAB) with particular focus on transitioning to oral antibiotic therapy. Materials and Methods: This retrospective cohort study included children aged ≤ 19 years diagnosed with SAB over a 5-year period. The main outcome was poor clinical outcome related to SAB defined as (1) recurrence of SAB within 30 days after discontinuation of SAB treatment and (2) any-cause mortality within 30 days after detection of SAB. Results: Over a 5-year period, 88 SAB episodes of 76 unique patients were included. The most common source of SAB attributed to central line (n = 34), followed by osteoarticular (n = 24), infections. All patients received at least one day of intravenous (IV) antibiotics and treatment was switched to an oral agent in 45.5% of SAB episodes. Sources of SAB in the oral switch group were osteoarticular (n = 21), skin and soft tissue (n = 7), central line (n = 3), thrombophlebitis (n = 2), head and neck infection (n = 1), and unknown (n = 6). 30-day mortality and SAB recurrence within 30 days after initial treatment completion occurred in 3 and 5 SAB episodes, respectively. None of the patients in oral switch group had poor clinical outcomes. Conclusion: Our study results indicate that 30-day any-cause mortality and SAB-related mortality is low in children. Similar to growing adult literature, oral switch in SAB treatment was not associated with poor SAB outcomes in selected patients. Cite this article as: Demirhan S, Anosike BI. Clinical outcomes of oral antibiotic switch in children with Staphylococcus aureus bacteremia. Turk Arch Pediatr. 2024;59(5):469-475.
- 2 September 2024
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 59 (5) , 469-475
Open AccessClinical Outcomes of Oral Antibiotic Switch in Children with Staphylococcus aureus Bacteremia
Objective: Staphylococcus aureus is one of the leading causes of bacteremia in children. In this study, we aimed to evaluate our center’s experience on the etiology, management, and outcomes of pediatric Staphylococcus aureus bacteremia (SAB) with particular focus on transitioning to oral antibiotic therapy. Materials and Methods: This retrospective cohort study included children aged ≤ 19 years diagnosed with SAB over a 5-year period. The main outcome was poor clinical outcome related to SAB defined as (1) recurrence of SAB within 30 days after discontinuation of SAB treatment and (2) any-cause mortality within 30 days after detection of SAB. Results: Over a 5-year period, 88 SAB episodes of 76 unique patients were included. The most common source of SAB attributed to central line (n = 34), followed by osteoarticular (n = 24), infections. All patients received at least one day of intravenous (IV) antibiotics and treatment was switched to an oral agent in 45.5% of SAB episodes. Sources of SAB in the oral switch group were osteoarticular (n = 21), skin and soft tissue (n = 7), central line (n = 3), thrombophlebitis (n = 2), head and neck infection (n = 1), and unknown (n = 6). 30-day mortality and SAB recurrence within 30 days after initial treatment completion occurred in 3 and 5 SAB episodes, respectively. None of the patients in oral switch group had poor clinical outcomes. Conclusion: Our study results indicate that 30-day any-cause mortality and SAB-related mortality is low in children. Similar to growing adult literature, oral switch in SAB treatment was not associated with poor SAB outcomes in selected patients. Cite this article as: Demirhan S, Anosike BI. Clinical outcomes of oral antibiotic switch in children with Staphylococcus aureus bacteremia. Turk Arch Pediatr. 2024;59(5):469-475.
- 11 February 2023
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 60 (2-3) , 78-79
Bugs under the skin: Traveller's foot
- 11 February 2023
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 60 (2-3) , 78-79
Bugs under the skin: Traveller's foot